Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Sanofi Appoints David Meeker Chief Executive Officer of Genzyme

share with twitter share with LinkedIn share with facebook
10/24/2011 | 11:20am EDT

October 24, 2011 10:30 AM Eastern Daylight Time 

PARIS--(BUSINESS WIRE)--Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the appointment of David Meeker as Chief Executive Officer of Genzyme, a Sanofi company, effective November 1, 2011. He will report to Christopher A. Viehbacher, Chief Executive Officer of Sanofi, and will join the Group Management Committee. Christopher A. Viehbacher will retain the position of Chairman, Genzyme.

"David's commitment to employees, physicians and patients has been a key success factor in the successful integration of Genzyme as part of the Sanofi Group. His combination of medical and business experience will be essential to move Genzyme's broad portfolio of products forward and deliver much-needed therapies to patients."

"After working closely with David over the past six months, I am confident that he is the best person to lead Genzyme," said Christopher A. Viehbacher, Chief Executive Officer of Sanofi. "David's commitment to employees, physicians and patients has been a key success factor in the successful integration of Genzyme as part of the Sanofi Group.His combination of medical and business experience will be essential to move Genzyme's broad portfolio of products forward and deliver much-needed therapies to patients."

Under David Meeker's leadership, Genzyme will incorporate the Rare Disease business and the Multiple Sclerosis franchise. Previous Genzyme divisions - Renal, Biosurgery and Oncology - have been integrated within the existing Sanofi portfolio giving them greater global scale and capabilities.

David joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Over the years he has held key positions of increasing responsibility as he led the development of treatments in the current rare disease portfolio. As President of the Global Rare Disease Business, he oversaw the global launches of Aldurazyme®, Fabrazyme® and Myozyme®. In 2009, he was promoted to Chief Operating Officer of Genzyme and has played an important role in the integration since April of this year. David received his M.D. from the University of Vermont Medical School, and completed the Advanced Management Program at Harvard Business School in 2000.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

share with twitter share with LinkedIn share with facebook
Latest news "Companies"
05:59pURBAN GRO : Announces Financial Results for 2020 Second Quarter
AQ
05:58pKEY ENERGY SERVICES : Reports Second Quarter 2020 Earnings
AQ
05:58pFEDERAL AGRICULTURAL MORTGAGE : Farmer Mac Prices $120 Million of Series E Preferred Stock
PU
05:58pB3 S A BRASIL BOLSA BALCÃO : Rca - 13/08/2020
PU
05:58pB3 S A BRASIL BOLSA BALCÃO : Bm 08/13/2020
PU
05:53pKader Exports Recalling Bags of Shrimp
PU
05:52pU.S. JUSTICE DEPARTMENT GOING 'FULL TILT' ON TECH ANTITRUST PROBE : official
RE
05:52pEATON : Launches New Line of Wireless Mobile Control Solutions for Heavy Machinery and Field Operations
BU
05:51pHOLLYSYS AUTOMATION : Fiscal 4Q Earnings Snapshot
AQ
05:49pSINGAPORE TECHNOLOGIES ENGINEERING : First-Half Net Fell 4%
DJ
Latest news "Companies"